Literature DB >> 21345425

The use of ultrasound to diagnose hepatic steatosis in type 2 diabetes: intra- and interobserver variability and comparison with magnetic resonance spectroscopy.

R M Williamson1, E Perry, S Glancy, I Marshall, C Gray, L D Nee, P C Hayes, S Forbes, B M Frier, G I Johnston, A J Lee, R M Reynolds, J F Price, M W J Strachan.   

Abstract

AIM: To compare ultrasound gradings of steatosis with fat fraction (FF) on magnetic resonance spectroscopy (MRS; the non-invasive reference standard for quantification of hepatic steatosis), and evaluate inter- and intraobserver variability in the ultrasound gradings.
MATERIALS AND METHODS: Triple grading of hepatic ultrasound examination was performed by three independent graders on 131 people with type 2 diabetes. The stored images of 60 of these individuals were assessed twice by each grader on separate occasions. Fifty-eight patients were pre-selected on the basis of ultrasound grading (normal, indeterminate/mild steatosis, or severe steatosis) to undergo (1)H-MRS. The sensitivity and specificity of the ultrasound gradings were determined with reference to MRS data, using two cut-offs of FF to define steatosis, ≥9% and ≥6.1%.
RESULTS: Median (intraquartile range) MRS FF (%) in the participants graded on ultrasound as normal, indeterminate/mild steatosis, and severe steatosis were 4.2 (1.2-5.7), 4.1 (3.1-8.5) and 19.4 (12.9-27.5), respectively. Using a liver FF of ≥6.1% on MRS to denote hepatic steatosis, the unadjusted sensitivity and specificity of ultrasound gradings (severe versus other grades of steatosis) were 71 and 100%, respectively. Interobserver agreement within one grade was observed in 79% of cases. Exact intraobserver agreement ranged from 62 to 87%.
CONCLUSION: Hepatic ultrasound provided a good measure of the presence of significant hepatic steatosis with good intra- and interobserver agreement. The grading of a mildly steatotic liver was less secure and, in particular, there was considerable overlap in hepatic FF with those who had a normal liver on ultrasound.
Copyright © 2011 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21345425     DOI: 10.1016/j.crad.2010.09.021

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  11 in total

1.  A Pilot Comparative Study of Quantitative Ultrasound, Conventional Ultrasound, and MRI for Predicting Histology-Determined Steatosis Grade in Adult Nonalcoholic Fatty Liver Disease.

Authors:  Jeremy S Paige; Gregory S Bernstein; Elhamy Heba; Eduardo A C Costa; Marilia Fereirra; Tanya Wolfson; Anthony C Gamst; Mark A Valasek; Grace Y Lin; Aiguo Han; John W Erdman; William D O'Brien; Michael P Andre; Rohit Loomba; Claude B Sirlin
Journal:  AJR Am J Roentgenol       Date:  2017-03-07       Impact factor: 3.959

2.  The epidemiology, clinical, biochemical, immunological and radiological features of youth onset type 2 diabetes mellitus in the state of Qatar.

Authors:  Shayma M Ahmed; Basma Haris; Saras Saraswathi; Ahmed Elawwa; Amal Khalifa; Maryam AlMaadheed; Tasneem R Abdel-Karim; Noor Hamed; Houda Afyouni; Hajar Dauleh; Ahmed Shamekh; Mahmoud Al-Zyoud; Fawziya AlKhalaf; Goran Petrovski; Khalid Hussain
Journal:  Diabetol Int       Date:  2021-10-11

3.  A history of previous gestational diabetes mellitus is associated with adverse changes in insulin secretion and VLDL metabolism independently of increased intrahepatocellular lipid.

Authors:  S Forbes; I F Godsland; S D Taylor-Robinson; J D Bell; E L Thomas; N Patel; G Hamilton; K H Parker; I Marshall; C D Gray; D Bedford; M Caslake; B R Walker; D G Johnston
Journal:  Diabetologia       Date:  2013-06-13       Impact factor: 10.122

4.  Short- and Long-Term Reproducibility of Intrahepatic Lipid Quantification by 1H-MR Spectroscopy and CT in Obesity.

Authors:  Laura E Dichtel; Alireza Eajazi; Karen K Miller; Martin Torriani; Miriam A Bredella
Journal:  J Comput Assist Tomogr       Date:  2016 Sep-Oct       Impact factor: 1.826

5.  Anatomical criteria to measure the adult right liver lobe by ultrasound.

Authors:  Bárbara L Riestra-Candelaria; Wilma Rodriguez-Mojica; Juan Carlos Jorge
Journal:  Sonography       Date:  2018-09-17

6.  Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study.

Authors:  Rachel M Williamson; Jackie F Price; Stephen Glancy; Elisa Perry; Lisa D Nee; Peter C Hayes; Brian M Frier; Liesbeth A F Van Look; Geoffrey I Johnston; Rebecca M Reynolds; Mark W J Strachan
Journal:  Diabetes Care       Date:  2011-04-08       Impact factor: 19.112

7.  Glucocorticoid treatment and impaired mood, memory and metabolism in people with diabetes: the Edinburgh Type 2 Diabetes Study.

Authors:  Rebecca M Reynolds; Javier Labad; Alison V Sears; Rachel M Williamson; Mark W J Strachan; Ian J Deary; Gordon D O Lowe; Jackie F Price; Brian R Walker
Journal:  Eur J Endocrinol       Date:  2012-03-09       Impact factor: 6.664

8.  γ-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study.

Authors:  Joanne R Morling; Jonathan A Fallowfield; Rachel M Williamson; Christine M Robertson; Stephen Glancy; Indra N Guha; Mark W J Strachan; Jackie F Price
Journal:  Diabetologia       Date:  2015-03-29       Impact factor: 10.122

9.  Effects of acute glucocorticoid blockade on metabolic dysfunction in patients with Type 2 diabetes with and without fatty liver.

Authors:  D P Macfarlane; P J Raubenheimer; T Preston; C D Gray; M E Bastin; I Marshall; J P Iredale; R Andrew; B R Walker
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-08-07       Impact factor: 4.052

10.  Clinically significant chronic liver disease in people with Type 2 diabetes: the Edinburgh Type 2 Diabetes Study.

Authors:  J R Morling; J A Fallowfield; I N Guha; R M Williamson; M Ali; S Glancy; M W J Strachan; J F Price
Journal:  QJM       Date:  2015-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.